Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? - Wikidata - awgldk - TriplyDB

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?

http://www.wikidata.org/entity/Q37778640

about

Vaccines for gonorrhea: can we rise to the challenge?Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future Preparing for an era of untreatable gonorrhea The use of cephalosporins for gonorrhea: an update on the rising problem of resistance.Antimicrobial resistance in Neisseria gonorrhoeae in the UK: surveillance and management.Antimicrobial stewardship - can we afford to do without it?Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone.Emergence of quinolone resistance and cephalosporin MIC creep in Neisseria gonorrhoeae isolates from a cohort of young men in Kisumu, Kenya, 2002 to 2009.Sublethal exposure to commercial formulations of the herbicides dicamba, 2,4-dichlorophenoxyacetic acid, and glyphosate cause changes in antibiotic susceptibility in Escherichia coli and Salmonella enterica serovar Typhimurium.High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure First comprehensive evaluation of the M.I.C. evaluator device compared to Etest and CLSI reference dilution methods for antimicrobial susceptibility testing of clinical strains of anaerobes and other fastidious bacterial species Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future.Emergence of decreased susceptibility and resistance to extended-spectrum cephalosporins in Neisseria gonorrhoeae in Korea.Current epidemiology and growing resistance of gram-negative pathogens.In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae Management of gonococcal infection among adults and youth: New key recommendations.Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae Assessment of self taken swabs versus clinician taken swab cultures for diagnosing gonorrhoea in women: single centre, diagnostic accuracy study Antimicrobial resistance in Neisseria gonorrhoeae and Treponema pallidum: evolution, therapeutic challenges and the need to strengthen global surveillance A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea New Ceftriaxone- and Multidrug-Resistant Neisseria gonorrhoeae Strain with a Novel Mosaic penA Gene Isolated in Japan.Antimicrobial Resistance Expressed by Neisseria gonorrhoeae: A Major Global Public Health Problem in the 21st Century.Utility of specimens positive for Neisseria gonorrhoeae by the Aptima Combo 2 assay for assessment of strain diversity and antibiotic resistance Assessment of Etest as an alternative to agar dilution for antimicrobial susceptibility testing of Neisseria gonorrhoeae Is gonorrhea becoming untreatable?Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials.Managing sexually transmitted infections in pregnant women.The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting.Current and future treatment options for gonorrhoea.Moving forward in tackling antimicrobial resistance: WHO actions.Gonococcal antimicrobial resistance: perspectives from the African region.Gonococcal antimicrobial resistance in the Western Pacific Region.New treatment options for infections caused by increasingly antimicrobial-resistant Neisseria gonorrhoeae.Persistence of Neisseria gonorrhoeae DNA following treatment for pharyngeal and rectal gonorrhea is influenced by antibiotic susceptibility and reinfection.Combination therapy for gonorrhoea: in vitro synergy testing.Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015.Management of Gonorrhea in Adolescents and Adults in the United States.

P2860

Q21131153-24241AE9-8396-48A7-8B1F-65F4215EE5D0 Q24633203-D09BA300-C728-4746-829E-6F17458F0A9D Q26796265-A4B8DD70-9874-424F-946F-6737BA999808 Q26862597-55443AD5-6C42-4FDE-BD76-C6CF18F742B9 Q27002771-2B153B96-D38E-4505-853A-FD09B0185134 Q33836057-7E2E354F-857F-40C5-B096-DD0BC8B455CB Q34632863-10FFBF36-B029-45B0-A15D-3D8D8D837CA4 Q35023684-BDCC7777-4036-4150-AA69-4B1E511267A9 Q35065794-2EA09532-3E3F-47FA-97C6-EF0DB06383E7 Q35139554-E0F579FF-EE18-432E-B151-F02D74ECC097 Q35677458-78F0C8CD-39DD-4C3F-8DE2-45623D3F4AAB Q35806206-AB9ED08A-C18C-4BBC-8F49-8A6BFD2FE02E Q35867842-78EE38B9-5636-4D10-B67A-B2C66790881B Q35878450-A574EE3B-B3F6-4ACF-AA21-BB9313B50091 Q35962785-C3375C7E-365E-4252-9CFE-E7A909FED5DF Q36025192-D1176CCE-7B08-4A9F-8640-5797523C5BB1 Q36086360-89E748AE-88F0-415F-A902-56683D80C22D Q36136318-AE1869DE-1311-425A-B923-185F626DB83C Q36166278-FEA96D08-5016-4313-A6EF-8340467175A2 Q36360329-0A13E6A5-E97D-4646-ABB9-59E5E750DC84 Q36462151-CD445ED7-A3D7-4C82-9F51-CAB5B381C289 Q36723212-14F0D8CC-8429-448C-86F6-BDF4BB49F545 Q36811237-68A717A2-FE16-41AD-BECE-016C17DC7ED0 Q37023276-9626A3B1-DA19-40A9-A458-98D787201673 Q37036002-06D49F3C-4C7C-4224-9780-673DD56F7CE8 Q37336216-0E8840C8-CF93-4760-A5DF-D423C786D92E Q37713705-977B9455-D6F0-41C9-B543-86A5562AE276 Q37844851-0F82542B-11B4-4478-B289-EC590550505C Q37994153-B6E56FA1-7D1F-4758-9FD3-544566615CBC Q38007203-BC085414-DF75-4F4E-92FB-A35FBCED4BC8 Q38011099-0CE48133-9E67-471B-956D-4FA9F42AA356 Q38150832-823A5930-BF8F-4510-A8B1-AEA1BC24EEB2 Q38160730-39751ABB-582C-401F-99C5-170F9B49DBF1 Q38163511-699FABD1-7B14-4A34-8E05-04EB7A583E06 Q38163512-3C7B9156-BECE-4628-96FE-E7EFCDE64A3D Q38675370-BBD24A71-468B-48CE-AB75-EF60194CA56F Q39129305-CD4FA7F2-C4EF-4C97-A9C9-F95C2BD2027B Q39519913-81790149-BD48-4229-801D-3043D74DE531 Q40053318-CE95D514-7DE2-410B-8583-9DE6D456CB73 Q40279995-B5346518-5D76-43A3-8615-EAC12D4A08DA

P2860

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?

http://www.wikidata.org/entity/Q37778640

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 August 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?

@en

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?

@nl

type

label

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?

@en

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?

@nl

prefLabel

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?

@en

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?

@nl

P1433

Q37778640-D734C06A-57F5-4632-AC3E-86AB2CA57F5F

P1476

Q37778640-8837CC1E-5140-4101-A29C-3E8A3D3D115B

P2093

Q37778640-13AFDB08-8AAE-4CEB-A477-8F4A9251D9B3

Q37778640-6E1FA905-13F0-4A08-8324-12263C7F994E

Q37778640-99A562E2-838F-463D-99C0-EED2ACE77BC3

Q37778640-9A94D74F-3B7A-4D73-987E-2593CBF770B1

Q37778640-A7361BBD-46FB-4EE0-B095-89E19B569E4C

P2860

Q37778640-16C26A3A-7D83-4E44-89A1-2937F31BB8A7

Q37778640-341EC78C-047F-490A-9972-7C21D01B7A15

Q37778640-3FCC6CFE-2551-4AF4-9A6A-216EAFD90C11

Q37778640-3FDED5CE-51A2-4245-8EE4-61DB5A06104C

Q37778640-4777FE84-7BD1-4188-B8A1-33A48163F5DD

Q37778640-4937EDD9-333E-4FBD-9996-F0F2B0B4A9F6

Q37778640-5316F8B4-580C-4FF8-A51D-387D3D3939FB

Q37778640-603BF220-64F6-4FD0-904E-1FD5293DC176

Q37778640-618B8FA6-B7D9-4366-A3F8-78A39652CE91

Q37778640-6FD1A3B5-E3DC-4C5E-A47C-3BD6CF809B21

P304

Q37778640-B1A283D7-CD75-4611-AB56-6F24073DF17F

P31

Q37778640-8B2422A8-A7DA-439C-B2EC-A6483324FA10

P356

Q37778640-3B0327EC-C105-4B29-AA1C-BD7A0E72B1FC

P407

Q37778640-9D55BE3A-9A92-4CBC-9153-F1C67479CB87

P433

Q37778640-56D68651-FE60-45B3-A854-F3E4B63F3B0F

P478

Q37778640-1D225875-83F2-4A3A-8935-2448327AE7EB

P50

Q37778640-5694CCED-5D22-46D3-B0FF-B6E7D5BFCE9C

P577

Q37778640-0775C01E-9210-4ECD-8FC8-B63BC836F993

P5875

Q37778640-AFEF56B5-699E-40C1-92BD-5FD4A62F54A5

P698

Q37778640-CEBB2354-6D38-48F1-89F3-D4A43A6B2691

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?

@en

P2093

Catherine A Ison

http://www.w3.org/2001/XMLSchema#string

David A Lewis

http://www.w3.org/2001/XMLSchema#string

David M Livermore

http://www.w3.org/2001/XMLSchema#string

Stephanie A Chisholm

http://www.w3.org/2001/XMLSchema#string

Tom Nichols

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents

Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone.

Mosaic-like structure of penicillin-binding protein 2 Gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime.

Which cephalosporin for gonorrhoea?

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.

Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers

Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.

Pharmacokinetic determinants of penicillin cure of gonococcal urethritis.

Pharmacokinetics and tissue penetration of a single dose of ceftriaxone (1,000 milligrams intravenously) for antibiotic prophylaxis in thoracic surgery.

Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies.

P304

2141-2148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKQ289

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45537791

http://www.w3.org/2001/XMLSchema#string

P698

20693173

http://www.w3.org/2001/XMLSchema#string